Schott Pharma reported a solid performance in the third quarter of the fiscal year 2025.

In Q3 2025, revenues increased by 1% to €256 million (approximately $299 million).

This corresponds to a 3% year-over-year (YOY) growth at constant currencies.

The development reflects a particularly strong prior-year quarter, which benefited from high demand, especially in the Drug Delivery Systems (DDS) segment.

The main revenue driver in Q3 was the Drug Containment Solutions (DCS) segment, particularly for high-value solutions (HVS).

Across the group, HVS accounted for 60% of revenues in Q3, with sterile solutions and specialty vials serving as key contributors.

Andreas Reisse, CEO of Schott Pharma, said: “Our strong high-value solutions performance underscores the strength of our strategy built on innovation and trustful partnerships within the industry, even in a volatile market environment.

“This positions Schott Pharma ideally to deliver solutions that meet the evolving needs of a dynamic, yet attractive market.”

In addition, EBITDA was €83 million, an increase of 11%.

Investments

To meet the increasing demand and continue the growth of HVS revenue, Schott Pharma has expanded its capacities.

In Hungary, the company is investing over €100m to build additional manufacturing capacities for sterile ready-to-use (RTU) cartridges.

The demand for these cartridges is rapidly increasing, largely driven by the growing need for diabetes and obesity therapies.

Sustainability

Starting in 2027, Schott Pharma plans to reduce its Scope 3 greenhouse gas emissions.

This initiative is bolstered by Schott, which has commenced construction on its first electric melting tank powered with 100% green electricity.

This technology and optimised, future-ready glass tubing is designed to significantly cut the Product Carbon Footprint (PCF) of drug containment and delivery solutions.

For example, the PCF for typical drug containment solutions such as vials can be reduced by approximately 30% compared to the current technology.

Outlook

The company now expects organic revenue growth of around 6.0% and an EBITDA margin of around 28.0% for the fiscal year 2025.

Given the continued HVS momentum, Schott Pharma is confident that the long-term pharma trends will sustain attractive market dynamics.

CFO appointed

Starting August 1, 2025, Schott Pharma has appointed Reinhard Mayer as its Chief Financial Officer.

Mr Mayer brings with him a wealth of experience in corporate finance, controlling, and IT, including more than 20 years in CFO positions, most recently at Denmark-listed Nilfisk Holding.

He expressed his enthusiasm for joining Schott Pharma, stating: “I’m eager to drive the company’s success story in the coming years and build upon this strong foundation with the Schott Pharma team.”

His leadership is expected to enhance the company’s strategic financial direction and reinforce its market position.